The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PROK | +35% | N/A | N/A | -73% |
| S&P | +13.96% | +91.24% | +13.85% | +59% |
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.22M | 0.0% |
| Gross Profit | -$1.27M | -31.7% |
| Gross Margin | -574.66% | 0.0% |
| Market Cap | $76.70M | -73.5% |
| Market Cap / Employee | $0.38M | 0.0% |
| Employees | 204 | 25.2% |
| Net Income | -$36.97M | 3.9% |
| EBITDA | -$38.22M | 9.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $84.94M | -60.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.52M | -37.7% |
| Short Term Debt | $0.90M | -12.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -16.64% | -8.8% |
| Return On Invested Capital | -44.45% | 16.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.53M | 11.3% |
| Operating Free Cash Flow | -$31.42M | 18.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.25 | -0.22 | -0.11 | -0.08 | -44.47% |
| Price to Sales | 2847.53 | 369.31 | 146.88 | - | |
| Price to Tangible Book Value | -0.25 | -0.22 | -0.11 | -0.08 | -44.47% |
| Enterprise Value to EBITDA | -26.48 | -28.01 | -28.91 | -29.54 | 3.06% |
| Total Debt | $6.44M | $3.24M | $3.37M | $4.42M | -33.78% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
